Crystal Structures of Protein Phosphatase-1 Bound to Nodularin-R and Tautomycin: A Novel Scaffold for Structure-based Drug Design of Serine/Threonine Phosphatase Inhibitors

Journal of Molecular Biology

Volumn 385, Issue 1, 2009, Pages 11-21

  Kelker, Matthew S ^a   Page, Rebecca ^b   Peti, Wolfgang ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

crystal structure; molecular toxins; nodularin R; protein phosphatase 1; tautomycin

Indexed keywords

ENZYME INHIBITOR; NODULARIN; PHOSPHOPROTEIN PHOSPHATASE 1; SERINE THREONINE PHOSPHATASE INHIITOR; TAUTOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG DESIGN; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TOXIN STRUCTURE;

EID: 57749209868     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.10.053     Document Type: Article

References (51)

1. Bollen M. Combinatorial control of protein phosphatase-1. Trends Biochem. Sci. 26 (2001) 426-431
2. Bollen M. FASEB Summer Meeting (2008), Snowmass Village, CO, USA
3. Cohen P.T. Protein phosphatase 1 - targeted in many directions. J. Cell Sci. 115 (2002) 241-256
4. Holmes C.F., Maynes J.T., Perreault K.R., Dawson J.F., and James M.N. Molecular enzymology underlying regulation of protein phosphatase-1 by natural toxins. Curr. Med. Chem. 9 (2002) 1981-1989
5. Hart M.E., Chamberlin A.R., Walkom C., Sakoff J.A., and Mccluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg. Med. Chem. Lett. 14 (2004) 1969-1973
6. Rishton G.M. Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am. J. Cardiol. 101 (2008) 43D-49D
7. Aggen J.B., Humphrey J.M., Gauss C.M., Huang H.B., Nairn A.C., and Chamberlin A.R. The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: rational modifications imparting PP1 selectivity. Bioorg. Med. Chem. 7 (1999) 543-564
8. Gulledgea B.M., Aggena J.B., Huangb H.B., Nairnc A.C., and Chamberlin A.R. The microcystins and nodularins: cyclic polypeptide inhibitors of PP1 and PP2A. Curr. Med. Chem. 9 (2002) 1991-2003
9. Dounay A.B., and Forsyth C.J. Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor. Curr. Med. Chem. 9 (2002) 1939-1980
10. Kato Y., Fusetani N., Matsunaga S., Hashimoto K., Fujita S., and Furua T.J. Calyculin A, a novel antitumor metabolite from the mairne sponge Discodermia calyx. J. Am. Chem. Soc. 108 (1986) 2780-2781
11. Honkanen R.E., Dukelow M., Zwiller J., Moore R.E., Khatra B.S., and Boynton A.L. Cyanobacterial nodularin is a potent inhibitor of type 1 and type 2A protein phosphatases. Mol. Pharmacol. 40 (1991) 577-583
12. Cheng X.C., Kihara T., Kusakabe H., Magae J., Kobayashi Y., Fang R.P., et al. A new antibiotic, tautomycin. J. Antibiot. (Tokyo) 40 (1987) 907-909
13. Stampwala S.S., Bunge R.H., Hurley T.R., Willmer N.E., Brankiewicz A.J., Steinman C.E., et al. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. II. Isolation and characterization. J. Antibiot. (Tokyo) 36 (1983) 1601-1605
14. Wang G.S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol. 26 (1989) 147-162
15. Cruz P.G., Fernandez J.J., Norte M., and Daranas A.H. Belizeanic Acid: a potent protein phosphatase 1 inhibitor belonging to the okadaic Acid class, with an unusual skeleton. Chemistry 14 (2008) 6948-6956
16. Maynes J.T., Bateman K.S., Cherney M.M., Das A.K., Luu H.A., Holmes C.F., et al. Crystal structure of the tumor-promoter okadaic acid bound to protein phosphatase-1. J. Biol. Chem. 276 (2001) 44078-44082
17. Kita A., Matsunaga S., Takai A., Kataiwa H., Wakimoto T., Fusetani N., et al. Crystal structure of the complex between calyculin A and the catalytic subunit of protein phosphatase 1. Structure 10 (2002) 715-724
18. Goldberg J., Huang H.B., Kwon Y.G., Greengard P., Nairn A.C., and Kuriyan J. Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376 (1995) 745-753
19. Maynes J.T., Luu H.A., Cherney M.M., Andersen R.J., Williams D., Holmes C.F., et al. Crystal structures of protein phosphatase-1 bound to motuporin and dihydromicrocystin-LA: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins. J. Mol. Biol. 356 (2006) 111-120
20. Cho U.S., and Xu W. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445 (2007) 53-57
21. Xing Y., Xu Y., Chen Y., Jeffrey P.D., Chao Y., Lin Z., et al. Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell 127 (2006) 341-353
22. Maynes J.T., Perreault K.R., Cherney M.M., Luu H.A., James M.N., and Holmes C.F. Crystal structure and mutagenesis of a protein phosphatase-1:calcineurin hybrid elucidate the role of the beta12-beta13 loop in inhibitor binding. J. Biol. Chem. 279 (2004) 43198-43206
23. Gupta V., Ogawa A.K., Du X., Houk K.N., and Armstrong R.W. A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A. J. Med. Chem. 40 (1997) 3199-3206
24. Zhou B., Wang Z.X., Zhao Y., Brautigan D.L., and Zhang Z.Y. The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. J. Biol. Chem. 277 (2002) 31818-31825
25. Liu W., Sheppeck II J.E., Colby D.A., Huang H.B., Nairn A.C., and Chamberlin A.R. The selective inhibition of phosphatases by natural toxins: the anhydride domain of tautomycin is not a primary factor in controlling PP1/PP2A selectivity. Bioorg. Med. Chem. Lett. 13 (2003) 1597-1600
26. Sugiyama Y., Ohtani I.I., Isobe M., Takai A., Ubukata M., and Isono K. Molecular shape analysis and activity of tautomycin, a protein phosphatase inhibitor. Bioorg. Med. Chem. Lett. 6 (1996) 3-8
27. Holm L., and Sander C. Mapping the protein universe. Science 273 (1996) 595-603
28. Zhang L., Zhang Z., Long F., and Lee E.Y. Tyrosine-272 is involved in the inhibition of protein phosphatase-1 by multiple toxins. Biochemistry 35 (1996) 1606-1611
29. Moorhead G., Mackintosh R.W., Morrice N., Gallagher T., and Mackintosh C. Purification of type 1 protein (serine/threonine) phosphatases by microcystin-Sepharose affinity chromatography. FEBS Lett. 356 (1994) 46-50
30. Colby D.A., Liu W., Sheppeck J.E., Huang H.B., Nairn A.C., and Chamberlin A.R. A new model of the tautomycin-PP1 complex that is not analogous to the corresponding okadaic acid structure. Bioorg. Med. Chem. Lett. 13 (2003) 1601-1605
31. Mitsuhashi S., Matsuura N., Ubukata M., Oikawa H., Shima H., and Kikuchi K. Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1. Biochem. Biophys. Res. Commun. 287 (2001) 328-331
32. Frydrychowski V.A., Urbanek R.A., Dounay A.B., and Forsyth C.J. Importance of the C28-C38 hydrophobic domain of okadaic acid for potent inhibition of protein serine-threonine phosphatases 1 and 2A. Bioorg. Med. Chem. Lett. 11 (2001) 647-649
33. Kawamura T., Matsuzawa S., Mizuno Y., Kikuchi K., Oikawa H., Oikawa M., et al. Different moieties of tautomycin involved in protein phosphatase inhibition and induction of apoptosis. Biochem. Pharmacol. 55 (1998) 995-1003
34. Xu Y., Xing Y., Chen Y., Chao Y., Lin Z., Fan E., et al. Structure of the protein phosphatase 2A holoenzyme. Cell 127 (2006) 1239-1251
35. Rauh R., Kahl S., Boechzelt H., Bauer R., Kaina B., and Efferth T. Molecular biology of cantharidin in cancer cells. Chin. Med. 2 (2007) 8
36. Mccluskey A., Sim A.T., and Sakoff J.A. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem. 45 (2002) 1151-1175
37. Sakoff J.A., and Mccluskey A. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Curr. Pharm. Des. 10 (2004) 1139-1159
38. Tatlock J.H., Linton M.A., Hou X.J., Kissinger C.R., Pelletier L.A., Showalter R.E., et al. Structure-based design of novel calcineurin (PP2B) inhibitors. Bioorg. Med. Chem. Lett. 7 (1997) 1007-1012
39. Peti W., and Page R. Strategies to maximize heterologous protein expression in Escherichia coli with minimal cost. Protein Expr. Purif. 51 (2007) 1-10
40. Mccoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D 61 (2005) 458-464
41. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50 (1994) 760-763
42. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
43. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53 (1997) 240-255
44. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60 (2004) 2126-2132
45. Winn M.D., Isupov M.N., and Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D 57 (2001) 122-133
46. Lamzin V.S., and Wilson K.S. Automated refinement of protein models. Acta Crystallogr. D 49 (1993) 129-147
47. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (2007) W375-W383
48. Vriend G. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph. 8 (1990) 52-56 29
49. Laskowski R.A., Macarthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
50. Schuttelkopf A.W., and Van Aalten D.M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D 60 (2004) 1355-1363
51. Terwilliger T.C., Grosse-Kunstleve R.W., Afonine P.V., Moriarty N.W., Adams P.D., Read R.J., et al. Iterative-build OMIT maps: map improvement by iterative model building and refinement without model bias. Acta Crystallogr. D 64 (2008) 515-524